BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Lone Star Bio

  SpinalCyte, LLC Announces 25th Patent

  The company has received confirmation of the issuance of European Patent No. 2776556, “Fibroblasts For Treatment Of Degenerative Disc Disease.”

  December 27, 2017

   · 

  1 min read
• 

  BioMidwest

  PharMEDium Issues Voluntary Nationwide Recall of Certain Lots of Compounded Sterile Products Due to Lack of Sterility Assurance

  To date, PharMEDium has not received any reports of complaints related to the products but is issuing this recall out of an abundance of caution following a commitment made during a recent inspection of the company’s facility.

  December 27, 2017

   · 

  14 min read
• Policy

  CStone Files CS1003, an Anti-PD-1 Antibody, for Clinical Trial Approval in Australia

  CStone today announced that a formal application for clinical trial approval has been submitted to Human Research Ethics Committees of the Scientia Clinical Research center in Australia for the anti-programmed death-1 (PD-1) mAb candidate CS1003.

  December 27, 2017

   · 

  4 min read
• Business

  HTG Molecular Diagnostics Expands its Collaboration With Merck KGaA, Darmstadt, Germany

  The Master Collaboration Agreement complements the previously announced Master Companion Diagnostic Agreement with Merck KGaA.

  December 27, 2017

   · 

  4 min read
• Drug Development

  Actinium Pharmaceuticals Provides Update on Pivotal Phase III Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue

  Actinium expects enhanced awareness of Iomab-B at ASH annual meeting and expanded site activity to enable completion of trial enrollment by end of 2018, in-line with prior forecast.

  December 27, 2017

   · 

  10 min read
• Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program - Dec. 27, 2017

  The purpose of the grant of warrants is to reflect the Company’s objective to incentivize long-term shareholder value creation.

  December 27, 2017

   · 

  2 min read
• 

  Policy

  FDA Extends Review Date of Portola’s AndexXa BLA App

  The FDA communicated that the action date will move from February 3, 2018 to May 4, 2018.

  December 27, 2017

   · 

  3 min read
• Pharm Country

  Helius Medical Technologies Announces Closing of First Tranche of Private Placement

  The net proceeds of the Private Placement will be used by the Company to finance the Company’s near-term operations and more.

  December 27, 2017

   · 

  8 min read
• Deals

  Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd.

  Under the deal, Summit acquired 100% of the issued share capital of Discuva.

  December 27, 2017

   · 

  9 min read
• GN Store Nord: Transactions in Relation to Share Buyback Program – Dec. 27, 2017

  The share buyback program has been initiated in order to reduce the company’s share capital and to cover obligations under the long-term incentive program.

  December 27, 2017

   · 

  2 min read